Since the frequent lack of hormone receptors (ER/PR) or Her2 extensively narrows the application of (anti-) endocrine therapies, BRCA1 associated breast cancers require a specially tailored therapeutic regimen [7]. Here, BRCA1 is linked to breast carcinoma.